Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Mechanisms of Cell-to-Cell Transmission of Pathological Tau
Garrett S. Gibbons, Virginia M.‐Y. Lee, John Q. Trojanowski
JAMA Neurology (2018) Vol. 76, Iss. 1, pp. 101-101
Open Access | Times Cited: 200

Showing 1-25 of 200 citing articles:

Alzheimer's disease
José Arguedas López, Hector M. González, Gabriel C. Léger
Handbook of clinical neurology (2019), pp. 231-255
Closed Access | Times Cited: 635
Aggregated Tau activates NLRP3–ASC inflammasome exacerbating exogenously seeded and non-exogenously seeded Tau pathology in vivo
Ilie‐Cosmin Stancu, Niels Cremers, Hannah Vanrusselt, et al.
Acta Neuropathologica (2019) Vol. 137, Iss. 4, pp. 599-617
Open Access | Times Cited: 345
Distribution patterns of tau pathology in progressive supranuclear palsy
Gábor G. Kovács, Milica Ječmenica‐Lukić, David J. Irwin, et al.
Acta Neuropathologica (2020) Vol. 140, Iss. 2, pp. 99-119
Open Access | Times Cited: 323
Tau biomarkers in Alzheimer's disease: towards implementation in clinical practice and trials
Rik Ossenkoppele, Rik van der Kant, Oskar Hansson
The Lancet Neurology (2022) Vol. 21, Iss. 8, pp. 726-734
Open Access | Times Cited: 288
Functional brain architecture is associated with the rate of tau accumulation in Alzheimer’s disease
Nicolai Franzmeier, Julia Neitzel, Anna Rubinski, et al.
Nature Communications (2020) Vol. 11, Iss. 1
Open Access | Times Cited: 264
A phosphoinositide signalling pathway mediates rapid lysosomal repair
Xiaojun Tan, Toren Finkel
Nature (2022) Vol. 609, Iss. 7928, pp. 815-821
Open Access | Times Cited: 220
Tau: Enabler of diverse brain disorders and target of rapidly evolving therapeutic strategies
Che-Wei Chang, Qiang Shao, Lennart Mucke
Science (2021) Vol. 371, Iss. 6532
Open Access | Times Cited: 194
Trem2 restrains the enhancement of tau accumulation and neurodegeneration by β-amyloid pathology
Seung-Hye Lee, William J. Meilandt, Luke Xie, et al.
Neuron (2021) Vol. 109, Iss. 8, pp. 1283-1301.e6
Open Access | Times Cited: 188
Association of Apolipoprotein E ε4 With Medial Temporal Tau Independent of Amyloid-β
Joseph Therriault, Andréa Lessa Benedet, Tharick A. Pascoal, et al.
JAMA Neurology (2019) Vol. 77, Iss. 4, pp. 470-470
Open Access | Times Cited: 186
Amyloid structures: much more than just a cross-β fold
Rodrigo Gallardo, Neil A. Ranson, Sheena E. Radford
Current Opinion in Structural Biology (2019) Vol. 60, pp. 7-16
Open Access | Times Cited: 180
Rutin prevents tau pathology and neuroinflammation in a mouse model of Alzheimer’s disease
Xiaoying Sun, Lingjie Li, Quan-xiu Dong, et al.
Journal of Neuroinflammation (2021) Vol. 18, Iss. 1
Open Access | Times Cited: 179
It’s all about tau
Cheril Tapia‐Rojas, Fabian Cabezas-Opazo, Carol A. Deaton, et al.
Progress in Neurobiology (2018) Vol. 175, pp. 54-76
Open Access | Times Cited: 163
Cellular and pathological heterogeneity of primary tauopathies
Dah‐eun Chloe Chung, Shanu F. Roemer, Leonard Petrucelli, et al.
Molecular Neurodegeneration (2021) Vol. 16, Iss. 1
Open Access | Times Cited: 141
Molecular signatures underlying neurofibrillary tangle susceptibility in Alzheimer’s disease
Marcos Otero-García, Sameehan Mahajani, Debia Wakhloo, et al.
Neuron (2022) Vol. 110, Iss. 18, pp. 2929-2948.e8
Open Access | Times Cited: 119
Tau strains shape disease
Jaime Vaquer‐Alicea, Marc I. Diamond, Łukasz A. Joachimiak
Acta Neuropathologica (2021) Vol. 142, Iss. 1, pp. 57-71
Open Access | Times Cited: 115
Safety and Efficacy of Semorinemab in Individuals With Prodromal to Mild Alzheimer Disease
Edmond Teng, Paul T. Manser, Karen Pickthorn, et al.
JAMA Neurology (2022) Vol. 79, Iss. 8, pp. 758-758
Open Access | Times Cited: 113
Tau deposition patterns are associated with functional connectivity in primary tauopathies
Nicolai Franzmeier, Matthias Brendel, Leonie Beyer, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 74
Integrated multimodal cell atlas of Alzheimer’s disease
Mariano I. Gabitto, Kyle J. Travaglini, Victoria M. Rachleff, et al.
Nature Neuroscience (2024)
Open Access | Times Cited: 61
Alzheimer’s disease: insights into pathology, molecular mechanisms, and therapy
Qiuyang Zheng, Xin Wang
Protein & Cell (2024)
Open Access | Times Cited: 27
Amyloid-beta and phosphorylated tau in post-mortem Alzheimer’s disease retinas
Jurre den Haan, Tjado H. J. Morrema, Frank D. Verbraak, et al.
Acta Neuropathologica Communications (2018) Vol. 6, Iss. 1
Open Access | Times Cited: 163
Small Heat Shock Proteins, Big Impact on Protein Aggregation in Neurodegenerative Disease
Jack M. Webster, April L. Darling, Vladimir N. Uversky, et al.
Frontiers in Pharmacology (2019) Vol. 10
Open Access | Times Cited: 146
18F-flortaucipir PET to autopsy comparisons in Alzheimer’s disease and other neurodegenerative diseases
David N. Soleimani‐Meigooni, Leonardo Iaccarino, Renaud La Joie, et al.
Brain (2020) Vol. 143, Iss. 11, pp. 3477-3494
Open Access | Times Cited: 123
4-Repeat tau seeds and templating subtypes as brain and CSF biomarkers of frontotemporal lobar degeneration
Eri Saijo, Michael A. Metrick, Shunsuke Koga, et al.
Acta Neuropathologica (2019) Vol. 139, Iss. 1, pp. 63-77
Open Access | Times Cited: 119
Retinal changes in Alzheimer's disease— integrated prospects of imaging, functional and molecular advances
Veer Bala Gupta, Nitin Chitranshi, Jurre den Haan, et al.
Progress in Retinal and Eye Research (2020) Vol. 82, pp. 100899-100899
Open Access | Times Cited: 117
Safety and efficacy of anti-tau monoclonal antibody gosuranemab in progressive supranuclear palsy: a phase 2, randomized, placebo-controlled trial
Tien Dam, Adam L. Boxer, Lawrence I. Golbe, et al.
Nature Medicine (2021) Vol. 27, Iss. 8, pp. 1451-1457
Closed Access | Times Cited: 103
Page 1 - Next Page

Scroll to top